- Notícias
- Galenicum Health obtains approval for Anastrozole in Brazil
- GSI USA participates in the Probiota Americas congress
- Good news for generics companies: European Commission refines intellectual property rules
- We inaugurated the new Galenicum's Office in Peru
- Galenicum Health is getting prepared for the upcoming pharmaceutical events of 2018
- Galenicum Special Ingredients makes The Financial Times 1000 List of Europe's Fastest Growing Companies in 2018
- Galenicum's new team in Colombia
- Galenicum Health assists to the DCAT Week in New York
- Galenicum Health in the peruvian news
- Galenicum Special Ingredients participates in Food Ingredients China
- Galenicum Health Peru launches its first OTC product
- Galenicum Health submits the dossier for Paracetamol in Spain
- Galenicum Health to launch in Southeast Asia
- Galenicum Health Peru will launch the food supplement line STOP&GO
- Galenicum Health Peru and the Dominican Republic are launching dexketoprofen
- Galenicum Health obtains the bioequivalence studies for Sitagliptin/Metformin combination
- GSI will attend the Nutraceuticals Europe Summit & Expo 2018 in Madrid
- Silanes and Galenicum Health launch dexketoprofen in Mexico
- Galenicum Health Peru and Chile launch a new business unit focused on pain relief with dexketoprofen and celecoxib
- Galenicum obtains the approval of the DCP of Anagrelide
- GSI attends the FI Europe 2017 in Frankfurt
- Galenicum participates in the 8th Edition of ESADE Innovation Quest
- FDA takes unprecedented step toward more efficient global pharmaceutical manufacturing inspections
- Galenicum enters agreement with Optibiotix to commercialise LPLDL® strain
- Galenicum will top €100 million in sales for the first time ever this year
- Galenicum attends the CPhI Worldwide 2017 in Frankfurt
- World International Day against Breast Cancer
- World Mental Health Day 2017: MENTAL HEALTH IN THE WORKPLACE
- GSI EEUU participates in Supply Side West 2017
- World Alzheimer's Day
- Galenicum Health Peru launches new intensive care business unit
- Galenicum launches Dutasteride in the European Market
- World Hepatitis Day
- Galenicum obtains DCP approval for Tigecycline
- Galenicum launches the new food supplement brand STOP&GO in Spanish pharmacies
- The importance of bioequivalence studies explained on Peruvian radio
- Galenicum obtains approval for first injectable product
- Galenicum launches in the Dominican Republic
- Galenicum at CPhI 2016
- The experiences of Sofía and Gabriel in the Hospital without Pain
- Galenicum, awarded for entrepreneurial trajectory
- Hospital without Pain. Story of Cristina, Victor’s mother.
- Share life, give blood
- SAG manufacturing has been certified by ANVISA
- Galenicum organizes the 3rd Workshop of Alzheimer Disease
- The success of Galenicum Health Peru in the last cardiology event of the country
- The bioequivalent medicines of Galenicum Health are already available in the main cities of Peru
- Galenicum with the World Health Day
- 3rth edition of University Joins Industry, once again a success
- Once again Galenicum as one of the companies with more patent submissions
- Biosimilar products, the challenge of the XXI century
- Past and future of Galenicum Health Peru
- Galenicum and Hospital Sant Joan de Déu making children’s life easier
- Galenicum challenges ESADE students
- Galenicum participates in the conference “Destination Peru, country of opportunities”
- Galenicum breaks new ground at the CPhI
- Generic drugs stand now for a 40% of the total pharmaceutical market in Spain
- The AEMPS boosts bioequivalence in Latin America through training
- Bioequivalent drugs, one of Peru’s main goals for the next year
- The false myths about generic medicines
- Galenicum, one step ahead of the generics
- Galenicum bring us closer to the generics world
- Galenicum and Parc Sanitari Sant Joan de Déu launch an innovative health guide
- GSI towards a new horizon
- The Peruvian Doctors Association reflects the need of implementing the bioequivalence studies as a measure of safety and effectiveness of generic drugs
- Galenicum, referent company on bioequivalent drugs, on Peruvian TV
- Galenicum, second Spanish pharmaceutical company in patent applications in 2014
- Galenicum, guest of honor at the Spain National Champions reception of the European Business Awards 2014/15
- Galenicum advances in developing its product pipeline
- Galenicum attended CPhI Worldwide 2014 in Paris
- Galenicum challenges the participants in the ESADE Innovation Quest 2014
- Galenicum, Business of the Year in the European Business Awards 2013/14
- Galenicum profiles its first launches for 2014
- Galenicum participates in the ETSEIB Forum 2014
- Galenicum and Uriach introduce Cilostazol in Sweden and UK
- Galenicum shortlisted in top 100 at European Business Awards 2013/14
- Sant Joan de Déu Barcelona Children’s Hospital and Galenicum join forces against child pain
- Galenicum shows its commitment to training by participating in University Joins Industry
- Galenicum attended CPhI Worlwide 2013 in Frankfurt
- Galenicum participates in the ESADE Innovation Quest 2013
- Galenicum among the National Champions of the European Business Awards 2013/14
- Galenicum hosts first edition of Innovation Awards
- Galenicum submits dossier for Almotriptan in several European countries
- Galenicum gets Marketing Authorizations for Dexketoprofen sachets in Spain
- Galenicum grows with a view to internationalisation
- Galenicum and Laboratorios Rubió sign a distribution agreement for Rubifen in Peru
- Galenicum opens new offices in Peru
- Galenicum announces successful bioequivalence study for Dutasteride
- Galenicum celebrates the yearly cocktail at CPhI
- Galenicum at CPhI Worldwide 2012
- Galenicum enters the Brazil market
- Galenicum presents its Strategy Board
- Galenicum attends the EuroPLX 45 in Portugal
- Qc LAB extensions passes GMP inspection
- Positive outcome of CPhi
- New investments in the lab for Quality Control for our customers
Notícias
Galenicum Health obtains the bioequivalence studies for Sitagliptin/Metformin combination
February 16, 2018
During the month of January, Galenicum Health received the bioequivalence studies of Sitagliptin/Metformin with a positive result.
This new combination is one of the most innovative drugs indicated for the treatment of diabetes with the potential advantage of administering fewer oral forms in each shot.
Galenicum expands the portfolio in this key therapeutic area for the company in the future. In 2017, Galenicum already obtained the bioequivalence studies of Sitagliptin monotherapy and Vildagliptin monotherapy.
